Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 1 year
- Director since
- 2026
1 year of board service in total across 2 boards, counting each seat separately. Longest: Vera Therapeutics Inc., 8 months.
Vera Therapeutics Inc.
Director
Kailera Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Royalty Pharma plc | Grant or award | +7,122 | — | — |
| Sep 22, 2026 | Royalty Pharma plc | Open-market sale | −96,073 | $58.51 | $5,621,231 |
| Sep 22, 2026 | Royalty Pharma plc | Open-market sale | −3,927 | $58.93 | $231,418 |
| Aug 19, 2026 | Royalty Pharma plc | Gift | −16,800 | — | — |
| Aug 18, 2026 | Royalty Pharma plc | Open-market sale | −100,000 | $59.97 | $5,997,000 |
| Aug 5, 2026 | Royalty Pharma plc | Grant or award | +11,002 | — | — |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −97,446 | $56.50 | $5,505,699 |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −2,554 | $57.10 | $145,833 |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −29,400 | $56.44 | $1,659,336 |
| Jun 30, 2026 | Royalty Pharma plc | Open-market sale | −600 | $57.09 | $34,254 |
| Jun 23, 2026 | Royalty Pharma plc | Open-market sale | −32,408 | $54.11 | $1,753,597 |
| Jun 23, 2026 | Royalty Pharma plc | Open-market sale | −117,592 | $54.47 | $6,405,236 |
| May 6, 2026 | Royalty Pharma plc | Grant or award | +24,263 | — | — |
| Feb 11, 2026 | Royalty Pharma plc | Grant or award | +26,626 | — | — |
Questions about Christopher Hite
What boards is Christopher Hite on?
Christopher Hite sits on the boards of Kailera Therapeutics Inc. and Vera Therapeutics Inc.
How long has Christopher Hite served on boards?
Our records show at least 1 year of board service across 2 boards, the earliest from 2026.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.